Peptidomimetic 3CLpro Inhibitors for SARS-CoV-2 Treatment

Solution Overview

Problem

Current treatments for SARS-CoV-2 infections lack effective vaccines and antiviral drugs, and existing protease inhibitors are not adequately addressing the replication of coronaviruses like SARS-CoV-2 due to high conservation of 3CLpro across human coronaviruses, necessitating a more targeted therapeutic approach.

Innovation Solution

Development of novel peptidomimetic compounds specifically designed as 3CLpro inhibitors, formulated into pharmaceutical compositions for effective treatment of coronavirus infections, demonstrating superior inhibition activity, cytotoxicity, phototoxicity, solubility, and stability profiles while minimizing Cytochrome P450 inhibition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing protease inhibitors are used, then viral replication can be inhibited, but the inhibition activity is insufficient due to high conservation of 3CLpro across human coronaviruses

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing peptidomimetic compounds with specific local structural features that target conserved regions of the 3CLpro enzyme. The compounds contain a warhead group (such as alpha-ketoamide, alpha-hydroxy amide, or hydroxamic acid) that specifically interacts with the catalytic cysteine residue in the active site, while the peptidomimetic backbone mimics the natural substrate sequence that is highly conserved across human coronaviruses. This localized optimization of binding interactions at critical regions enhances inhibition activity while accommodating the high conservation of the target enzyme.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying key structural parameters of the protease inhibitor molecules, including the warhead group type, amino acid side chains at specific positions (P1, P2, P3, etc.), and molecular flexibility. These parameter optimizations are designed to maximize binding affinity and inhibition potency against the highly conserved 3CLpro active site, thereby improving reliability of viral replication inhibition while maintaining adaptability to the conserved target structure.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If novel peptidomimetic compounds are developed, then inhibition activity is improved, but complexity of compound structure increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the peptidomimetic compound into distinct functional segments: a warhead group (such as alpha-ketoamide, alpha-hydroxy amide, or hydroxamic acid) for covalent or strong non-covalent binding to the catalytic cysteine, a peptidomimetic backbone segment that mimics the natural substrate and provides specificity, and optional terminal groups for optimizing pharmacokinetic properties. This modular segmentation allows systematic optimization of inhibition activity while managing structural complexity through defined functional units.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent employs composite material principles by combining different chemical moieties into a single peptidomimetic molecule: the warhead group (with specific reactivity), the peptidomimetic backbone (with substrate-like sequence), and auxiliary groups (for solubility, stability, or metabolic resistance). This composite structure integrates multiple functional properties into one molecule, achieving high inhibition activity while the systematic composition helps manage overall structural complexity through defined functional contributions.

Inventive Principle:
Principle #40Composite materials

3Reliability

If protease inhibitors are administered, then viral replication is inhibited, but cytotoxicity and other safety issues arise

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies the intermediary principle by using the peptidomimetic structure as a mediator that mimics the natural viral substrate sequence, allowing specific recognition and binding to the 3CLpro active site while avoiding off-target interactions. The peptidomimetic backbone acts as an intermediary between the warhead group and the viral enzyme, providing substrate-like recognition that enhances selectivity. This mediating structure reduces cytotoxicity by directing the inhibitor's action specifically toward the viral protease rather than host cell components.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs copying by designing peptidomimetic compounds that replicate key features of the natural viral substrate sequence recognized by 3CLpro. The compounds copy the essential structural and sequence characteristics of the authentic substrate that the enzyme normally processes, enabling highly specific binding to the viral protease active site. This copying approach ensures that the inhibitor selectively targets the viral enzyme while minimizing interactions with host cell proteases, thereby reducing cytotoxicity while maintaining potent inhibition activity.

Inventive Principle:
Principle #26Copying

Data Source

PatentUS12060333B2Aminocarbamoyl compounds for the treatment of viral infections
Publication Date: 2024.08.13
  • US12060333B2 patent drawing
  • US12060333B2 patent drawing
  • US12060333B2 patent drawing

AI summary

The present invention relates to compounds of formula (I),wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.